Streetbeat News

Products Services

TNXP

Tonix Pharmaceuticals presented additional safety and tolerability data from the RESILIENT Phase 3 study of TNX-102 SL for fibromyalgia management at Biotech Showcase 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:17 pm

NUWE

Nuwellis has been granted a U.S. patent (#11865302) for an extracorporeal blood filtering machine and methods. This patent could potentially enhance the company's product portfolio and provide a competitive edge in the medical device market. The patent grant may also open up new opportunities for partnerships or licensing agreements, and it could serve as a barrier to entry for competitors.

Portfolio Pulse from Charles Gross

January 09, 2024 | 12:14 pm

MCRB

Seres Therapeutics has been granted FDA Fast Track designation for SER-155, a microbiome therapeutic aimed at preventing gastrointestinal-associated bacterial infections. The Phase 1b placebo-controlled Cohort 2 data for SER-155 is expected to be released in the third quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:14 pm

MCRB

Seres Therapeutics reported preliminary unaudited net sales of $10.4M for Q4 2023, with total net sales of $19.6M since the June 2023 launch of Vowst. The sales figures reflect a gross-to-net reduction of 13%. The company saw significant adoption of Vowst, with 2,833 patient enrollment forms received and 2,015 new patient starts by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:11 pm

CYN

Cyngn Inc. has been granted its 18th US patent, US-11,837,090-B2, for adaptive traffic rule-based decision making in autonomous driving. This technology is designed to optimize driving decisions for autonomous vehicles when faced with multiple environmental rules or constraints.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:09 pm

LASE

Laser Photonics Corporation (NASDAQ:LASE), a developer of CleanTech laser systems, has received an order from Laserweld Inc. for its LPC-1500-CTHD laser blasting system. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:06 pm

F

RIVN

TSLA

Tesla Inc.'s (NASDAQ:TSLA) price cuts in 2023 have significantly reduced the price gap between electric vehicles (EVs) and internal combustion engine (ICE) vehicles. Cox Automotive reports that by December, the average Tesla vehicle price was $50,051, close to the average ICE vehicle price of $48,759. The average EV price also dropped to $50,798. High inventory levels for EVs were reported, but Tesla and Rivian Automotive Inc. (NASDAQ:RIVN) were excluded from this data. The University of Exeter suggests EVs may become more affordable than gas vehicles in the U.S. this year. Ford Motor Co (NYSE:F) paused its $12 billion EV funding due to high EV costs and customer reluctance.

Portfolio Pulse from Ramakrishnan M

January 09, 2024 | 12:04 pm

MDWD

MediWound announced that the FDA has accepted for review the supplement to the NexoBrid Biologics License Application (BLA) to include treatment for pediatric patients with severe thermal burns. This acceptance could potentially expand the use of NexoBrid to a broader patient population.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:03 pm

EXK

Endeavour Silver Corp. reported its full year 2023 production, totaling 5.7 million ounces of silver and 37,858 ounces of gold, which equates to 8.7 million silver equivalent ounces. The fourth quarter contributed 1.4 million ounces of silver and 9,440 ounces of gold to this total.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:55 am

GMAB

PFE

The FDA has accepted a priority review for Genmab and Pfizer's supplemental Biologics License Application to convert the accelerated approval of Tivdak to full approval for recurrent or metastatic cervical cancer. The PDUFA action date is set for May 9.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:49 am